Edition:
United Kingdom

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

25,714.46ZAc
19 Jan 2018
Change (% chg)

114.46 (+0.45%)
Prev Close
25,600.00
Open
25,900.00
Day's High
25,952.00
Day's Low
25,464.00
Volume
2,811,837
Avg. Vol
1,498,950
52-wk High
32,750.00
52-wk Low
23,498.00

Latest Key Developments (Source: Significant Developments)

Aspen Pharmacare Receives Approval For Registration Of Alula In China​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - Aspen Pharmacare Holdings Ltd ::‍ASPEN RECEIVES APPROVAL FOR REGISTRATION OF ALULA IN CHINA​.  Full Article

Aspen Pharmacare Says Has Had No Contact With Viceroy Research
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Aspen Pharmacare Holdings Ltd ::HAS HAD NO CONTACT WITH VICEROY RESEARCH AND, AS SUCH, IS UNABLE TO CONFIRM THAT SPECULATION IS CORRECT.IS NOT AWARE OF ANY INFORMATION OF A PRICE SENSITIVE NATURE THAT REQUIRES COMMUNICATION TO SHAREHOLDERS​.  Full Article

Mylan And Aspen Announce Launch Of Generic Busulfex Injection
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Mylan Nv ::MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION.MYLAN NV - ‍ANNOUNCED U.S. LAUNCH OF MYLERAN INJECTION, 60 MG/10 ML SINGLE-DOSE VIAL, A GENERIC VERSION OF OTSUKA PHARMACEUTICAL'S BUSULFEX INJECTION​.  Full Article

Aspen Pharmacare says ‍UK CMA opens investigation against company
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Aspen Pharmacare Holdings Ltd :‍UK COMPETITION AND MARKETS AUTHORITY HAS OPENED AN INVESTIGATION AGAINST ASPEN​.‍INVESTIGATION INTO ANTI-COMPETITIVE CONDUCT ON SUPPLY OF FLUDROCORTISONE ACETATE 0.1 MG TABLETS, DEXAMETHASONE 2 MG TABLETS IN UK​.‍INVESTIGATION IS AT AN EARLY, INFORMATION-GATHERING STAGE.CMA CONFIRMED THAT, AT THIS TIME, IT HAS NOT REACHED ANY CONCLUSION ON WHETHER COMPETITION LAW HAS BEEN INFRINGED​.‍ASPEN IS NOT CURRENTLY IN A POSITION TO COMMENT ON INVESTIGATION​.  Full Article

Aspen Pharmacare says GSK sells remaining stake in co
Thursday, 29 Sep 2016 

Aspen Pharmacare Holdings Ltd : GSK completed an accelerated bookbuild for disposal of its remaining shareholding in aspen .Disposal in no way affects ongoing collaboration between aspen and GSK in South Africa.  Full Article

GSK gets 477 mln stg gross proceeds from Aspen Pharmacare stake sale
Thursday, 29 Sep 2016 

Glaxosmithkline Plc :Gross proceeds of Aspen transaction are equivalent to £477 million.  Full Article

GSK says to sell remaining stake in Aspen Pharmacare
Wednesday, 28 Sep 2016 

GlaxoSmithKline Plc : GSK intends to sell remaining holding in Aspen . Intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd . Offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately .Offering is expected to comprise up to 28.2 million Aspen ordinary shares equivalent to 6.2 pct of Aspen's ordinary share capital.  Full Article

Aspen Pharmacare to buy exclusive rights to commercialise AstraZeneca's anaesthetics portfolio
Thursday, 1 Sep 2016 

Aspen Pharmacare Holdings Ltd : Had signed an agreement with AstraZeneca whereby AGI will acquire exclusive rights to commercialise astrazeneca's global (excluding USA) anaesthetics portfolio .Transaction was anticipated to complete during Q1 of Aspen's 2017 financial year.  Full Article

Astrazeneca completes Aspen agreement
Thursday, 1 Sep 2016 

Astrazeneca Plc : Astrazeneca completes Aspen agreement . Completes commercialisation agreement with Aspen for anaesthetics portfolio .Upfront payment, along with all future milestone and royalty payments, will be reported as externalisation revenue in company's financial statements.  Full Article

Aspen Pharmacare Holdings closes 3 bln euro facilities arrangements
Wednesday, 8 Jun 2016 

Aspen Pharmacare Holdings Ltd : Aspen closes eur 3,000,000,000 equivalent facilities arrangements . Initial launch size of eur 1.5 bn for eur facilities was significantly oversubscribed .BofAm, Barclays Bank Plc and ABSA Bank Limited acted as joint coordinators.  Full Article

Photo

Drugmaker GSK cuts back in Africa to hone emerging markets model

LONDON GlaxoSmithKline is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent.